Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer

DSpace/Manakin Repository

Search OPUS

Advanced Search


My Account

Show simple item record

dc.contributor.author Viney, RC
dc.contributor.author Boyer, MJ
dc.contributor.author King, MT
dc.contributor.author Kenny, PM
dc.contributor.author Pollicino, CA
dc.contributor.author McLean, JM
dc.contributor.author McCaughan, BC
dc.contributor.author Fulham, MJ
dc.date.accessioned 2009-12-21T02:34:55Z
dc.date.issued 2004
dc.identifier.citation Journal of Clinical Oncology, 2004, 22 (12), pp. 2357 - 2362
dc.identifier.issn 0732-183X
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/4826
dc.description.abstract Purpose: Positron emission tomography (PET) is a costly new technology with potential to improve preoperative evaluation for patients with non-small-cell lung cancer (NSCLC). There is increasing pressure for PET to be included in standard diagnostic work-up before decisions about surgical management of NSCLC. The resource implications of its widespread use in staging NSCLC are significant. Methods: A randomized controlled trial was conducted to investigate the impact of PET on clinical management and surgical outcomes for patients with stage I-II NSCLC. The primary hypothesis was that PET would reduce the proportion of patients with stage I-II NSCLC who underwent thoracotomy by at least 10% through identification of patients with inoperable disease. Results: One hundred eighty-four patients with stage I-II NSCLC were recruited and randomly assigned; 92% had stage I disease. Following exclusion of one ineligible patient, 92 patients were assigned to no PET and 91 to PET. Compared with conventional staging, PET upstaged 22 patients, confirmed staging in 61 and staged two patients as benign. Stage IV disease was rarely detected (two patients). PET led to further investigation or a change in clinical management in 13% of patients and provided information that could have affected management in a further 13% of patients. There was no significant difference between the trial arms in the number of thoracotomies avoided (P = .2). Conclusion: For patients who are carefully and appropriately staged as having stage I-II disease, PET provides potential for more appropriate stage-specific therapy but may not lead to a significant reduction in the number of thoracotomies avoided. © 2004 by American Society of Clinical Oncology.
dc.language eng
dc.relation.isbasedon 10.1200/JCO.2004.04.126
dc.title Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer
dc.type Journal Article
dc.description.version Published
dc.parent Journal of Clinical Oncology
dc.journal.volume 12
dc.journal.volume 22
dc.journal.number 12 en_US
dc.publocation Alexandria en_US
dc.identifier.startpage 2357 en_US
dc.identifier.endpage 2362 en_US
dc.cauo.name BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.conference 4th IEEE International Symposium on Signal Processing and Information Technology
dc.for 1112 Oncology and Carcinogenesis
dc.personcode 020117
dc.personcode 106668
dc.personcode 020118
dc.percentage 100 en_US
dc.classification.name Oncology and Carcinogenesis en_US
dc.classification.type FOR-08 en_US
dc.date.activity 2004-12-08
dc.location.activity Rome, ITALY
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Business
pubs.organisational-group /University of Technology Sydney/Strength - Health Economics and Research Evaluation
utslib.copyright.status Closed Access
utslib.copyright.date 2015-04-15 12:17:09.805752+10
pubs.consider-herdc true
utslib.collection.history Uncategorised (ID: 363)
utslib.collection.history Closed (ID: 3)

Files in this item

This item appears in the following Collection(s)

Show simple item record